Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to -$609000.0.

  • Aytu Biopharma's Change in Inventory rose 287.08% to -$609000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.1 million, marking a year-over-year decrease of 15284.67%. This contributed to the annual value of -$382000.0 for FY2025, which is 10792.37% down from last year.
  • Per Aytu Biopharma's latest filing, its Change in Inventory stood at -$609000.0 for Q4 2025, which was up 287.08% from -$1.1 million recorded in Q3 2025.
  • Aytu Biopharma's Change in Inventory's 5-year high stood at $2.1 million during Q3 2022, with a 5-year trough of -$7.2 million in Q2 2021.
  • Moreover, its 5-year median value for Change in Inventory was $284000.0 (2021), whereas its average is -$70800.0.
  • Per our database at Business Quant, Aytu Biopharma's Change in Inventory soared by 108202.25% in 2022 and then plummeted by 21616.77% in 2025.
  • Aytu Biopharma's Change in Inventory (Quarter) stood at $390000.0 in 2021, then crashed by 79.74% to $79000.0 in 2022, then skyrocketed by 765.82% to $684000.0 in 2023, then crashed by 191.67% to -$627000.0 in 2024, then increased by 2.87% to -$609000.0 in 2025.
  • Its Change in Inventory stands at -$609000.0 for Q4 2025, versus -$1.1 million for Q3 2025 and $518000.0 for Q2 2025.